AKI
2
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Elysium TherapeuticsOH - Akron
1 program1
Nicotinamide Riboside + PterostilbenePhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
UNION therapeuticstransdermal GFR
Renibus TherapeuticsLow Dose RBT-1
Elysium TherapeuticsNicotinamide Riboside + Pterostilbene
SeaStar MedicalSCD
Clinical Trials (4)
Total enrollment: 278 patients across 4 trials
mGFR vs tGFR in AKI
Start: Jun 2026Est. completion: May 202750 patients
Phase 4Not Yet Recruiting
Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery
Start: Aug 2021Est. completion: Feb 2023152 patients
Phase 2Completed
Protection From Acute Kidney Injury (AKI) With Basis™ Treatment
Start: Dec 2020Est. completion: Mar 202454 patients
Phase 2Completed
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
Start: Sep 2020Est. completion: Jul 202122 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.